Time for reflection on what was accomplished in 2020
ActiPatch Now Cleared for "All" Musculoskeletal Pain ...
2/21/2020 Orthopedic Design & Technology
BioElectronics Corporation, the maker of non-invasive electroceutical devices, has obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This over-the counter marketing clearance was granted for the drug free ActiPatch medical device, for the indication: “adjunctive treatment of musculoskeletal pain.”
********************************************************************
Richard Staelin, Ph.D. Rejoins the Board of BioElectronics Corporation
6/15/2020
We are pleased to welcome Dr. Staelin as an independent director and Chairman to BioElectronics Corporation’s board. Dr. Staelin rejoins BioElectronics at an exciting time as we continue to drive our OEM strategy forward and build deeper relationships with current international distributors to fulfill our purpose of helping people live pain free. We are confident he will provide valuable perspective as we continue to execute our strategy, drive profitability and enhance value for all shareholders.
***********************************************************************
BioElectronics Chairman Outlines New Direction for Company
8/10/2020
We now have signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. These three companies will be selling our devices into the United States over-the-counter (OTC) consumer health retail market.
We also have a signed agreement with a commercial firm that is in the process of recruiting and training up to 400 independent sales representatives who will actively sell our RecoveryRx postoperative pain product line into doctors’ offices, wound clinics, nursing facilities, and hospitals.
In terms of international sales, we recently signed a licensing agreement with a major international company and are in the final stages of signing an agreement with another large international company.
**********************************************************************
BioElectronics' ActiPatch® Therapy To Be Marketed By DonJoy® Advantage
11/6/2020
This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch". In January 2020, BioElectronics obtained a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the drug free ActiPatch® medical device, for the indication: "adjunctive treatment of musculoskeletal pain." With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.
https://www.donjoyperformance.com/eme-knee-wrap
*********************************************************************
BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices
11/12/2020
The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark.
***********************************************************************
Letter from the Chairman
11/26/2020
In summary, it has been a busy and productive year. The Company is moving in the right direction. Numerous new systems have been developed to support our new OEM strategy. Our core capabilities of R&D and expertise in designing and manufacturing Pulsed Short Wave Therapy devices have increased. The forecast for the next year has us above breakeven sales.
Internationally, we landed a contract with Adcock, a large firm in South Africa. Adcock is now in the process of registering the product and first sales to them should occur in early 2021. In addition, now that we have re-acquired our CE mark, we are able to reopen communications with our international distributors. We anticipate (or have already received) new orders from Romania, Italy, Australia, Sweden, the UK, and Spain.
*********************************************************************
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market
12/15/2020
BioElectronics Corporation (OTC PINK: BIEL), (www.bielcorp.com) is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
The agreement incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain.
**************************************************************************
Quite the Year but 2021 will bring even more !!!
ActiPatch Now Cleared for "All" Musculoskeletal Pain ...
2/21/2020 Orthopedic Design & Technology
BioElectronics Corporation, the maker of non-invasive electroceutical devices, has obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This over-the counter marketing clearance was granted for the drug free ActiPatch medical device, for the indication: “adjunctive treatment of musculoskeletal pain.”
********************************************************************
Richard Staelin, Ph.D. Rejoins the Board of BioElectronics Corporation
6/15/2020
We are pleased to welcome Dr. Staelin as an independent director and Chairman to BioElectronics Corporation’s board. Dr. Staelin rejoins BioElectronics at an exciting time as we continue to drive our OEM strategy forward and build deeper relationships with current international distributors to fulfill our purpose of helping people live pain free. We are confident he will provide valuable perspective as we continue to execute our strategy, drive profitability and enhance value for all shareholders.
***********************************************************************
BioElectronics Chairman Outlines New Direction for Company
8/10/2020
We now have signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. These three companies will be selling our devices into the United States over-the-counter (OTC) consumer health retail market.
We also have a signed agreement with a commercial firm that is in the process of recruiting and training up to 400 independent sales representatives who will actively sell our RecoveryRx postoperative pain product line into doctors’ offices, wound clinics, nursing facilities, and hospitals.
In terms of international sales, we recently signed a licensing agreement with a major international company and are in the final stages of signing an agreement with another large international company.
**********************************************************************
BioElectronics' ActiPatch® Therapy To Be Marketed By DonJoy® Advantage
11/6/2020
This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch". In January 2020, BioElectronics obtained a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the drug free ActiPatch® medical device, for the indication: "adjunctive treatment of musculoskeletal pain." With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.
https://www.donjoyperformance.com/eme-knee-wrap
*********************************************************************
BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices
11/12/2020
The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark.
***********************************************************************
Letter from the Chairman
11/26/2020
In summary, it has been a busy and productive year. The Company is moving in the right direction. Numerous new systems have been developed to support our new OEM strategy. Our core capabilities of R&D and expertise in designing and manufacturing Pulsed Short Wave Therapy devices have increased. The forecast for the next year has us above breakeven sales.
Internationally, we landed a contract with Adcock, a large firm in South Africa. Adcock is now in the process of registering the product and first sales to them should occur in early 2021. In addition, now that we have re-acquired our CE mark, we are able to reopen communications with our international distributors. We anticipate (or have already received) new orders from Romania, Italy, Australia, Sweden, the UK, and Spain.
*********************************************************************
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market
12/15/2020
BioElectronics Corporation (OTC PINK: BIEL), (www.bielcorp.com) is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
The agreement incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain.
**************************************************************************
Quite the Year but 2021 will bring even more !!!
3
1
